R&D Tax

The 2026–27 Federal Budget introduces potential changes to Australia’s Research & Development Tax Incentive (RDTI) regime, with a continued focus on innovation, productivity and business investment.

From updates to R&D tax offsets and eligibility rules to broader innovation funding measures, businesses undertaking research and development activities may need to review their tax strategies, compliance obligations and future investment plans.

Revamping the R&D Tax Incentive

In the wake of the Ambitious Australia report recommendation, the Government has announced several sweeping reforms to the Research and Development Tax Incentive (RDTI) regime that will take delayed effect from 1 July 2028:

  • Lifting the refundable R&D tax offset threshold from $20m to $50m aggregated turnover as recommended but tempering this potentially transformative development by limiting refundability to companies under 10 years old. Access to the higher R&D tax offset will subsequently still be available but it will not be refundable.  
  • Increasing the R&D expenditure cap from $150m to $200m, a move that will benefit only a handful of the largest R&D claimants but could restore some of Australia’s international competitiveness with other global R&D jurisdictions.  
  • Funding an increase in both refundable and non-refundable sets of R&D tax offset rates applying to core R&D activities by removing the eligibility of supporting R&D activity expenditures.
  • Raising the minimum R&D spend from $20,000 to $50,000 for all claimants, with lower spends still eligible only if undertaken with registered service providers (RSPs) or Cooperative Research Centres (CRCs).

The ATO will receive $2.8m in funding over three years from 2027-28 to support the implementation of these measures.  

Overall, the proposed amendments will significantly reduce R&D registration and costing compliance efforts and will disincentivise RDTI claims that are disproportionately made up of supporting activities.  

The increase in R&D minimum spend is not unexpected and fortunately less than the recommended threshold of $150,000, which would have wiped out a significant number of claimants. Nonetheless, a cash refund may be the difference between continuing or abandoning R&D. Whether collaboration vouchers, as recommended by Ambitious Australia, eventuate or indeed are an appropriate replacement mechanism will remain to be seen.

Regardless of any statutory changes announced, SMEs making RDTI claims will continue to face scrutiny from the ATO, which could reduce the overall positive economic impact of the changes made.

From a wider corporate tax perspective, the reintroduction of the loss carry back rules once again treats tax losses more favourably than excess non-refundable R&D tax offsets. This regime will disincentivise RDTI claims that increase the use of tax losses that could otherwise be carried back and create complexities between the two regimes.  

Similarly, the permanent increase in the $20,000 instant asset write-off for small business entities will also intensify the consequences of its relatively-little-understood interaction with the RDTI regime.  

WINNERS

  • R&D claimants with aggregated turnover of between $20m and $50m, especially those that will be less than 10 years old in FY29  
  • R&D claimants with proportionately low spend on supporting R&D activities  
  • Large multinationals with annual spend of between $150m and $200m  
  • Related R&D workforces  


 

LOSERS

  • Established refundable claimants more than 10 years old at FY29
  • R&D claimants with an annual spend of less than $50,000
  • R&D claimants with proportionately high spend on supporting R&D activities   

 CASE STUDY: 
 10-year refundable rule 

For FY29, AgriCo Pty Ltd is a nine year old company and is a BRE still in tax losses with an R&D spend of $1m. 
Under the current provisions, there is an R&D tax offset of $1.8m x (25% + 18.5%) = $783,000. 

Under the proposed amendments for FY29 onwards, there will be an R&D tax offset of $1m x (25% + 23%) = $480,000. 

Had the core activities been $1m and the supporting activities $300,000, the R&D tax offsets would have been $565,500 and $480,000 respectively.


 

 CASE STUDY: 
 Impact of removing eligibility of supporting R&D activities 

Core Co Pty Ltd is a BRE entitled to the refundable R&D tax offset, and has an R&D spend of $1m on core activities and $800,000 on supporting activities. 
An increased R&D tax offset of $480,000 will arise and will be refundable. However, in the following year FY30, the same level of spend would result in the same quantum of R&D tax offset being $480,000, but if in excess of tax payable, this would have to be carried forward and used subject to satisfaction of the loss utilisation tests. 

Note that after 10 years, the company does not start to fall under the non-refundable provisions; rather the quantum of the refundable offset becomes non-refundable. 

 CASE STUDY: 
 Reduction in intensity threshold 

MedTechCo Pty Ltd is a non-BRE entitled to the non-refundable R&D tax offset and total expenditure for the year of $30m. Eligible core R&D expenditure is $4m (an intensity of 13.33%). 
Under current rules, the 2% intensity threshold is $600,000 so the R&D tax offset = ($600,000 x 38.5%) + ($3.4m x 46.5%) = $1.812m. 

Under the proposed amendments, the reduced 1.5% intensity threshold is $450,000 so the R&D tax offset = ($450,000 x 43%) + ($3.55m x 51%) = $2.004m.

Notably, if MedTechCo had been a BRE between $20m and $50m, it would have moved from non-refundable to refundable status due to the increase in the turnover threshold to $50m. 

 

 CASE STUDY: 
 Increase in R&D expenditure cap

Mining Co spends $250m in an income year on eligible R&D activities and is eligible for the base tier of the non-refundable R&D tax offset. Under the current provisions, Mining Co can claim a 38.5% R&D tax offset rate on $150m and an R&D tax offset at the corporate tax rate of 30% on the remaining $100m = $87.75m. 
Under the proposed amendments for FY29 onwards, Mining Co will be able to claim the increased 43% R&D tax offset rate on $200m, and an R&D tax offset at the corporate tax rate of 30% on the remaining $50m = $101m. 


 

 CASE STUDY: 
 Interaction of RDTI and loss carry back regimes

Loss Co Pty Ltd has tax losses that could be carried back. The company has an option to make an RDTI claim that would result in excess non-refundable R&D tax offsets that would have to be carried forward. 
If an RDTI claim was made, increased tax losses would be deducted to offset the notionally deductible R&D expenditure that have been added back. The cash flow benefit of carrying back the tax losses that would be used, may exceed the future benefit of the R&D uplift. 

HAVE A QUESTION ABOUT THE FEDERAL BUDGET?

GET IN TOUCH WITH OUR EXPERTS

Additional insights